Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cancer Cytopathol. 2014 Feb;122(2):96-103. doi: 10.1002/cncy.21375. Epub 2013 Dec 11.
The objectives of this study were to evaluate the validity of Cervista human papillomavirus (HPV) assays in head and neck fine-needle aspiration (FNA) specimens from patients with head and neck squamous carcinomas and to verify that the Cervista assay in FNA specimens is a valid option for determining HPV status in patients with oropharyngeal carcinomas.
The authors retrospectively retrieved 64 head and neck FNA specimens from patients who had head and neck squamous carcinoma. The specimens were tested for HPV types 16 and 18 (HPV16/18) and for high-risk (HR) HPV DNA using the Cervista HPV16/18 and HPV HR assays, respectively. The results from those assays were compared with the results from polymerase chain reaction (PCR)-based HPV assays in the same tissues and with the results from HPV in situ hybridization assays/p16 immunostaining in the corresponding primary tumors.
In total, 64 FNA specimens were analyzed. The Cervista HPV16/18 and/or HPV HR assays were positive in 48 of 64 specimens (75%), and there was a predominance of HPV16 (42 of 48 specimens; 88%). In the 49 specimens that had PCR-based test results, overall agreement with Cervista assay results was 96% (47 of 49 specimens; κ = 0.883). In the 49 specimens that had PCR-based HPV16/18 genotyping results, overall agreement with the Cervista HPV16/18 results was 94% (46 of 49 specimens; κ = 0.847). In the 36 primary carcinoma specimens that had valid HPV in situ hybridization/p16 immunostaining results, overall agreement with the Cervista assay results was 92% (33 of 36 specimens; κ = 0.679).
Cervista HPV16/18 and Cervista HPV HR testing of head and neck FNA specimens is a valid option for determining HPV16/18 status in patients with oropharyngeal carcinoma.
本研究旨在评估 Cervista 人乳头瘤病毒（HPV）检测法在头颈部鳞癌患者细针抽吸（FNA）标本中的有效性，并验证 Cervista 检测法在 FNA 标本中是否是确定口咽癌患者 HPV 状态的有效方法。
作者回顾性收集了 64 例头颈部 FNA 标本，这些标本来自患有头颈部鳞癌的患者。使用 Cervista HPV16/18 和 HPV HR 检测法分别检测 HPV 型 16 和 18（HPV16/18）以及高危型（HR）HPV DNA。将这些检测结果与相同组织中聚合酶链反应（PCR）HPV 检测结果以及相应原发肿瘤中 HPV 原位杂交/ p16 免疫染色结果进行比较。
总共分析了 64 例 FNA 标本。48 例（75%）标本的 Cervista HPV16/18 和/或 HPV HR 检测呈阳性，其中 HPV16 占优势（42 例；88%）。在有基于 PCR 的检测结果的 49 例标本中，与 Cervista 检测结果的总体一致性为 96%（47 例；κ=0.883）。在有基于 PCR 的 HPV16/18 基因分型结果的 49 例标本中，与 Cervista HPV16/18 结果的总体一致性为 94%（46 例；κ=0.847）。在有有效 HPV 原位杂交/ p16 免疫染色结果的 36 例原发性癌标本中，与 Cervista 检测结果的总体一致性为 92%（33 例；κ=0.679）。
Cervista HPV16/18 和 Cervista HPV HR 对头颈部 FNA 标本的检测是确定口咽癌患者 HPV16/18 状态的有效选择。
